Glucadel | Gary R. Ostroff, founder
Gary R. Ostroff said his move to an MBI incubator worked backward from the normal path of research to commercialization.
"I graduated from the incubator in an unusual way because the company I started is no longer functionally in business. I have licensed some of the technology to other companies and I remain a consultant on the advisory board of companies," Ostroff said. Ostroff founded a company called Glucadel, which was eventually sold to Eden Research in the U.K. He is now a professor of molecular medicine at UMass Medical School.
Spin Offs
And in another twist, Ostroff has licensed some of the technology to UMass Medical School, which plans to license to other companies, reversing the usual license path from university to commercialization.
Ostroff said the flexibility at MBI incubators allows companies to succeed in different ways, helping them with office and lab space and finding expertise for when they need it.
The technology that Ostroff has developed allows for yeast cell walls to be used as an oral delivery mechanism for nanoparticles of DNA, RNA and other drugs.
In fact, a fellow incubator mate, Targeted Cell Therapies, has licensed some of Ostroff's work.
Ostroff's patented technology involves using the shell of a yeast cell wall , loading it with the drug or "payload" and a trapping polymer that binds to the drug, which all work together to deliver the drug to where it needs to go. His technology revolves around the interaction of the payload and the trapping polymer
Although Ostroff used the incubator lab to conduct his research, he also knows that at heart, he is a self-proclaimed lab rat and he doesn't want a corporate position.
WBJ Web Partners
Most Recent
Most Recent
0 Comments